A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Eisai Inc.
Eisai Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Virginia
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Providence Health & Services
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
University of California, San Diego
Sichuan Enray Pharmaceutical Sciences Company
Menarini Group
Boehringer Ingelheim
Pfizer
Thomas Jefferson University
Health Hope Pharma
Boehringer Ingelheim
Boehringer Ingelheim
Dana-Farber Cancer Institute
Daiichi Sankyo
NantBioScience, Inc.
Tesaro, Inc.
Vanderbilt-Ingram Cancer Center
Pfizer
Hoffmann-La Roche
Hutchmed
Pfizer
University of Washington
Pfizer
GlaxoSmithKline
Pfizer
Genentech, Inc.
Avera McKennan Hospital & University Health Center
Pfizer
Merck Sharp & Dohme LLC
Eisai Inc.
EVIVE Biotechnology
Pfizer
Hoffmann-La Roche
Duke University
Roswell Park Cancer Institute
Genentech, Inc.
Herlev Hospital
Daiichi Sankyo
Ludwig Institute for Cancer Research
Stanford University
Ludwig Institute for Cancer Research
OBI Pharma, Inc
National Institutes of Health Clinical Center (CC)